The industry’s capital has shifted dramatically into specialty therapies. The pricing grace period has been halved to 6 months. We fill your strategic key positions with precision and discretion.
Real risk management for your profitability.
An empty seat in this critical phase costs hard cash every single day. Exclusive headhunting in Germany for profiles in Medical Affairs, Marketing and Sales.
The industry’s portfolios are undergoing a fundamental restructuring, driven by intense shareholder pressure. Investors today demand clear pure-play strategies — no more mixed conglomerates. The market punishes unclear profiles with a steep valuation discount.
Focus on Pure Play and innovation
Economically, the market is splitting into a low-margin volume business and high-priced innovation. Investors demand a clean separation, they want to decide for themselves whether to invest in stable volume business or high-risk innovation.
Research-driven pharma companies have drawn the consequences and spun off their high-volume business to protect the core margin. Novartis successfully took Sandoz public, Johnson & Johnson carved out Kenvue, and Sanofi completed its exit from Opella.
The focus of these corporations now lies fully on high-margin specialty care. Every vacancy in this segment becomes a boardroom issue at once. Delays at launch jeopardise the commitments made to analysts — and with them the share price.
Primary Care and the volume business
Primary Care means basic medical provision. In economic terms, this market is today the domain of generics logic. It is governed by hard rebate contracts, a pure volume business focused on supply chain and tender management.
A classic field-force visit to a physician costs you between 150 and 200 euros in Germany today. With an average daily therapy dose of a few cents, that simply no longer adds up.
There are rare exceptions. True blockbusters such as Wegovy by Novo Nordisk or Zepbound by Eli Lilly for obesity treatment form lucrative islands of innovation. These products fall under the lifestyle provision of the German Social Code (SGB V): statutory health insurers do not reimburse them, and patients pay out of pocket. For manufacturers, that means full margin without AMNOG price pressure. Modern RSV vaccines likewise defend high margins in the primary-care market.
Specialty Care and the ticking clock
This is where your growth lies. Biopharmaceuticals today account for well over 33 percent of total German market revenue. Capital is flowing into oncology, immunology and rare diseases.
But the pressure on profitability is extreme from two sides. At launch, the law halves the grace period, after 6 months, free pricing is over. In parallel, the AMNOG revenue threshold for orphan drugs has been capped at 30 million euros. Successful niche products suddenly fall into full assessment.
At the same time, the clock is ticking at the end of the life cycle. Patent expiry threatens the industry’s existential revenues. Humira by AbbVie lost its exclusivity long ago and is feeling the heavy margin erosion from biosimilars. Eylea by Bayer lost its European protection in 2025. And for Keytruda by MSD, the enormous patent cliff of 2028 is drawing ever closer.
Whoever leads here must offset enormous revenue losses by building new pipelines. The remaining exclusivity window of today’s cash cows has to be defended without mercy.
The ticking
clock.
Whoever leads here must offset enormous revenue losses by building new pipelines. The remaining exclusivity window of today’s cash cows has to be defended without mercy.
You know the problems. We place the answer.
We see every day where launches are failing right now. It is rarely the global strategy that is missing. It is the right people in execution.
Your key opinion leaders demand rigorous scientific debate on real-world evidence. We place Medical Directors and Senior Medical Science Liaisons. These experts build trust with specialists as equals, long before the product reaches the market. Without an excellent medical team, your sales force later hits closed doors.
The days when a launch was steered solely through the frequency of field-force visits are over. In the specialist departments we often hear the phrase: “That is how we have always done it.” That mindset will get you nowhere in the new reality.
Specialists today demand a seamless omnichannel strategy. They want information on demand, through digital channels that do not disrupt their clinical day. What is needed are profiles that unite regulatory rigour and innovation. The courage to seize opportunities within strict compliance constraints becomes the decisive competitive edge.
We find you Heads of Marketing and Senior Product Managers who orchestrate specialty launches the modern way. These leaders master agile content management and break through internal approval bottlenecks. Anyone still thinking in silos loses touch with the audience.
The decision-making centre for specialty products has shifted dramatically. Classic selling in the doctor’s office is losing ground. More than 50 percent of specialists now refuse access for conventional visits. The relevant conversations take place in the office of commercial leadership, about budgets and supply contracts.
We find you the experts for strategic key account management. These profiles negotiate as equals with hospital networks and purchasing alliances. In parallel, we place leaders and high-impact experts for your international scale-up. This is where a single hire can move your profitability.
We accompany the profound shift among top talent. More and more high performers are turning down classic leadership roles. They define themselves not by FTE, but by measurable impact. These individual contributors often own portfolios of up to 100 million euros on their own. They want to shape outcomes. The leverage is enormous, unfilled positions cost millions.
The heterogeneous talent market in pharma
First things first: there is no single “pharma labour market”. That has always held across the different markets, Rx Specialty, OTC Consumer, CDMO and Biotech, their market mechanics are simply too different. But talent markets also differ within a single segment, especially in Specialty Pharma.
To understand it, you have to follow the money. Demand for talent moves with the flow of capital, with a lag of roughly 6 to 9 months. Where money is withdrawn, roles are cut sooner or later — for instance in the restructuring waves of broad-indication sales teams. Where capital flows in, demand for qualified specialists and leaders arises.
We see strong demand especially in oncology, immunology and rare diseases. This is where money is still made. Because of the €30M revenue threshold for rare diseases, we expect subdued demand in the short to medium term; the new rule will undoubtedly influence investment decisions.
Regardless of indication, one thing holds: the clock ticks mercilessly on every patent. Once protection expires, a price collapse of 80 percent looms. Companies have no time for long ramp-up phases.
The problem: the qualifications of those becoming available often don’t match the new challenges. Although the market has eased overall for employers, it is fiercely contested for the key positions of the future. Demographic change acts as an accelerant.
The industry-standard time to fill a role in pharma is over 150 days, almost the entire window of your free pricing. What unfilled roles really cost is documented in our own analyses of the economic impact for German pharma companies: revenue losses in the millions.
Top performers today look for purpose and self-efficacy. This clientele is not actively searching. We secure access to these passive talents through market depth and discretion. In an environment where classic recruiting approaches barely work anymore, personal dialogue is the only way.